Stockreport

Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019

Caladrius Biosciences, Inc.  (CLBS) 
Last caladrius biosciences, inc. earnings: 11/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: caladrius.com/investors/overview
PDF Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events CLBS16 cell therapy shows promise as a significant adva [Read more]